Skip to content
medxy logo

Medxy AI

  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
Hypertension-Related High-Risk Features May Identify Which Patients With Cryptogenic Stroke Benefit From Apixaban Instead of Aspirin
Posted inCardiology Neurology news

Hypertension-Related High-Risk Features May Identify Which Patients With Cryptogenic Stroke Benefit From Apixaban Instead of Aspirin

Posted by MedXY By MedXY 06/10/2026
An exploratory ARCADIA analysis suggests that patients with cryptogenic stroke and atrial cardiopathy without severe hypertension-related features may derive greater benefit from apixaban than aspirin, whereas those with high-risk hypertensive features may not.
Read More
A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib
Posted inDiabetes & Endocrinology news Oncology

A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib

Posted by MedXY By MedXY 06/10/2026
A 64-year-old man with RET-altered medullary thyroid carcinoma who progressed on selpercatinib achieved complete response after modified dosing of tarlatamab with manageable CRS/ICANS.
Read More
A Three-miRNA Plasma Signature May Help Detect Early Beta Cell Dysfunction Before Overt Type 2 Diabetes Progression
Posted inDiabetes & Endocrinology news Pathology & Lab Medicine/Bệnh học

A Three-miRNA Plasma Signature May Help Detect Early Beta Cell Dysfunction Before Overt Type 2 Diabetes Progression

Posted by MedXY By MedXY 06/10/2026
Plasma profiling identified a three-miRNA panel associated with beta cell rate sensitivity across glucose tolerance stages, suggesting a minimally invasive approach to detect early insulin secretory decline.
Read More
Culture-Negative Infective Endocarditis in the Modern Diagnostic Era: Patient Characteristics and Heterogeneity in a Nationwide Cohort
Posted inCardiology Infectious Diseases news

Culture-Negative Infective Endocarditis in the Modern Diagnostic Era: Patient Characteristics and Heterogeneity in a Nationwide Cohort

Posted by MedXY By MedXY 06/10/2026
A nationwide Danish study found that culture-negative infective endocarditis was less common than previously reported, often presented without fever or sepsis, and showed higher embolic risk. PET-CT was especially useful in prosthetic valve cases.
Read More
Silent Plaque Ruptures in Non-Obstructive Lesions of Non-Infarct-Related Arteries: What Serial Coronary Imaging Reveals
Posted inCardiology news

Silent Plaque Ruptures in Non-Obstructive Lesions of Non-Infarct-Related Arteries: What Serial Coronary Imaging Reveals

Posted by MedXY By MedXY 06/10/2026
In patients with acute myocardial infarction, silent plaque rupture was found in 12% of non-obstructive lesions in non-infarct-related arteries. Larger plaques, positive remodeling, and thinner fibrous caps were linked to rupture, and more than half of untreated ruptures healed over 52 weeks.
Read More
Low-Level Airborne Particulate Matter and Risk of Hypertension Hospitalization in Older U.S. Adults
Posted inCardiology news Public Health

Low-Level Airborne Particulate Matter and Risk of Hypertension Hospitalization in Older U.S. Adults

Posted by MedXY By MedXY 06/10/2026
A large U.S. study found that even PM2.5 levels below current federal standards were linked to higher hypertension hospitalization risk in older adults, especially among women and some regional and socioeconomic groups.
Read More
Individual GLP-1 Receptor Agonists and SGLT2 Inhibitors Show Largely Comparable Cardiovascular Protection in Type 2 Diabetes
Posted inCardiology Diabetes & Endocrinology news

Individual GLP-1 Receptor Agonists and SGLT2 Inhibitors Show Largely Comparable Cardiovascular Protection in Type 2 Diabetes

Posted by MedXY By MedXY 06/10/2026
A multinational real-world study found broadly similar cardiovascular effectiveness across individual GLP-1 receptor agonists and SGLT2 inhibitors in metformin-treated type 2 diabetes, including among patients with established cardiovascular disease.
Read More
Exploring the Impact of Body Mass Index on Heart Failure Outcomes: Insights from Mendelian Randomization
Posted inCardiology news

Exploring the Impact of Body Mass Index on Heart Failure Outcomes: Insights from Mendelian Randomization

Posted by MedXY By MedXY 06/10/2026
This study leverages Mendelian randomization to demonstrate that genetically elevated BMI is associated with increased mortality and adverse cardiovascular outcomes in heart failure, irrespective of ejection fraction status, underscoring potential benefits of weight management.
Read More
Oral NLRP3 Inhibition With Ruvonoflast Produces Rapid, Reversible Suppression of Residual Inflammation in Adults at High Cardiovascular Risk
Posted inCardiology Internal Medicine news

Oral NLRP3 Inhibition With Ruvonoflast Produces Rapid, Reversible Suppression of Residual Inflammation in Adults at High Cardiovascular Risk

Posted by MedXY By MedXY 06/10/2026
In a Phase 1b placebo-controlled trial, ruvonoflast markedly reduced hsCRP, IL-6, and fibrinogen over 28 days in adults with obesity, elevated hsCRP, and cardiometabolic risk, supporting further evaluation of oral NLRP3 inhibition in atherosclerotic prevention.
Read More
Low-Level Airborne Particulate Matter and Risk of Hypertension Hospitalization in Older U.S. Adults
Posted inCardiology news Public Health

Low-Level Airborne Particulate Matter and Risk of Hypertension Hospitalization in Older U.S. Adults

Posted by MedXY By MedXY 06/10/2026
Among more than 26 million older U.S. adults, even PM2.5 levels below current standards were linked to higher hypertension hospitalization risk, suggesting no clearly safe low-exposure threshold.
Read More
Body Mass Index, Clinical Outcomes, and Mortality in Heart Failure: A Mendelian Randomization Study
Posted inCardiology news

Body Mass Index, Clinical Outcomes, and Mortality in Heart Failure: A Mendelian Randomization Study

Posted by MedXY By MedXY 06/10/2026
This study uses Mendelian randomization to show that higher genetically predicted BMI is associated with increased all-cause mortality and cardiovascular events in heart failure patients, regardless of ejection fraction status.
Read More
Arrhythmia Burden and Clinical Responses Under Continuous Monitoring in Heart Failure: Observations From the ALLEVIATE-HF Trial
Posted inCardiology news

Arrhythmia Burden and Clinical Responses Under Continuous Monitoring in Heart Failure: Observations From the ALLEVIATE-HF Trial

Posted by MedXY By MedXY 06/10/2026
Continuous monitoring in heart failure patients revealed a high burden of arrhythmias linked to more interventions, hospitalizations, and heart failure events, but not altered by the study’s congestion-management strategy.
Read More
Arrhythmia Burden and Clinical Responses Under Continuous Monitoring in Heart Failure: Observations From the ALLEVIATE-HF Trial
Posted inCardiology Internal Medicine news

Arrhythmia Burden and Clinical Responses Under Continuous Monitoring in Heart Failure: Observations From the ALLEVIATE-HF Trial

Posted by MedXY By MedXY 06/10/2026
Continuous ICM monitoring in heart failure uncovered a high arrhythmia burden, including atrial fibrillation, bradyarrhythmia, and VT/VF, which was linked to more interventions, hospitalizations, and heart failure events.
Read More
A Mobility-Enabled Active Driver for Berlin Heart EXCOR Showed Zero Major Device Malfunctions in High-Risk Pediatric VAD Support
Posted inCardiology news Pediatrics

A Mobility-Enabled Active Driver for Berlin Heart EXCOR Showed Zero Major Device Malfunctions in High-Risk Pediatric VAD Support

Posted by MedXY By MedXY 06/10/2026
In a prospective multicenter study, the EXCOR Active Driver demonstrated excellent reliability and high short-term survival in children requiring ventricular assist support, while supporting a registry-enabled pathway for class III pediatric device evaluation.
Read More
Risk-Based Nurse-Managed Personalized Heart Failure Interventions: The ALLEVIATE-HF Trial
Posted inCardiology news

Risk-Based Nurse-Managed Personalized Heart Failure Interventions: The ALLEVIATE-HF Trial

Posted by MedXY By MedXY 06/10/2026
The ALLEVIATE-HF trial found that implantable monitor-based risk alerts with nurse-managed diuretic treatment were safe but did not significantly improve the main heart failure outcome composite.
Read More
Arrhythmia Burden and Clinical Responses Under Continuous Monitoring in Heart Failure: Findings from the ALLEVIATE-HF Trial
Posted inCardiology news

Arrhythmia Burden and Clinical Responses Under Continuous Monitoring in Heart Failure: Findings from the ALLEVIATE-HF Trial

Posted by MedXY By MedXY 06/10/2026
Continuous implantable monitoring in heart failure revealed a high burden of arrhythmias, strongly linked to hospitalizations and treatment changes, but not reduced by protocol-directed congestion management.
Read More
The Prognostic Value of Serum Interleukin-6 Concentrations for 9 Cardiovascular and Mortality Outcomes
Posted inCardiology news Public Health

The Prognostic Value of Serum Interleukin-6 Concentrations for 9 Cardiovascular and Mortality Outcomes

Posted by MedXY By MedXY 06/10/2026
Higher blood IL-6 levels were strongly linked to nine cardiovascular and mortality outcomes in nearly 60,000 adults, supporting IL-6 as an important inflammatory marker and potential prevention target.
Read More
Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study
Posted inDiabetes & Endocrinology news Ophthalmology

Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study

Posted by MedXY By MedXY 06/10/2026
In a large OHDSI network study of adults with type 2 diabetes, semaglutide was not associated with a higher or lower risk of neovascular age-related macular degeneration.
Read More
Lifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health: MRI-Based 5- and 10-Year Follow-Up After Two Clinical Trials
Posted inCardiology Diabetes & Endocrinology news

Lifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health: MRI-Based 5- and 10-Year Follow-Up After Two Clinical Trials

Posted by MedXY By MedXY 06/10/2026
Long-term follow-up after two lifestyle trials found that reductions in visceral fat, more than overall weight loss, were linked to sustained cardiometabolic benefits and a lower risk of type 2 diabetes.
Read More
Cagrilintide-Semaglutide (CagriSema) Lowers HbA1c Better Than Semaglutide Alone in Type 2 Diabetes
Posted inDiabetes & Endocrinology news

Cagrilintide-Semaglutide (CagriSema) Lowers HbA1c Better Than Semaglutide Alone in Type 2 Diabetes

Posted by MedXY By MedXY 06/10/2026
REIMAGINE 2 found that once-weekly cagrilintide-semaglutide lowered HbA1c more than semaglutide alone in adults with type 2 diabetes and overweight or obesity, with a safety profile consistent with known gastrointestinal effects.
Read More

Posts pagination

Previous page 1 … 3 4 5 6 7 … 272 Next page
  • Comparative 1-Year Outcomes of Semaglutide, Tirzepatide, and Sleeve Gastrectomy in Obese Adults with Type 2 Diabetes: Insights from Real-World Data
  • Unveiling the Phenotype of Unclassified Pulmonary Hypertension: A Hidden Spectrum of Early Heart Failure with Preserved Ejection Fraction
  • Biomarker, Functional Status, and Quality-of-Life Trajectories Before Modes of Death in Heart Failure: Post Hoc Analysis of the FINEARTS-HF Randomized Clinical Trial
  • Decoding SLC4A3 Mutations in Short QT Syndrome: Insights from hiPSC-Derived Cardiomyocytes into Ventricular Arrhythmia and Sudden Cardiac Death
  • Decade-Long Outcomes of SAPIEN 3 TAVR vs. Surgery in Intermediate-Risk Aortic Stenosis Patients
Post You Might Like
Posted inDiabetes & Endocrinology news
Comparative 1-Year Outcomes of Semaglutide, Tirzepatide, and Sleeve Gastrectomy in Obese Adults with Type 2 Diabetes: Insights from Real-World Data
Posted by MedXY By MedXY 06/20/2026
Posted inCardiology news Respiratory
Unveiling the Phenotype of Unclassified Pulmonary Hypertension: A Hidden Spectrum of Early Heart Failure with Preserved Ejection Fraction
Posted by MedXY By MedXY 06/20/2026
Posted inCardiology news
Biomarker, Functional Status, and Quality-of-Life Trajectories Before Modes of Death in Heart Failure: Post Hoc Analysis of the FINEARTS-HF Randomized Clinical Trial
Posted by MedXY By MedXY 06/20/2026
Posted inCardiology news
Decoding SLC4A3 Mutations in Short QT Syndrome: Insights from hiPSC-Derived Cardiomyocytes into Ventricular Arrhythmia and Sudden Cardiac Death
Posted by MedXY By MedXY 06/20/2026
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in